{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:41:06Z","timestamp":1787960466507,"version":"build-2784847793"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder affecting the skinfold regions. There is growing appreciation of the need for socioeconomic factors to be included in multidisciplinary assessments of HS. However, knowledge regarding HS and workplace function is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the relationship between HS and workplace function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CINAHL, Embase, MEDLINE, PsycINFO and PubMed were systematically searched to collect data from studies in which validated surveys of workplace function were administered to patients with HS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1932 publications, 12 studies were included in this review and 7 reported sufficient data for meta-analysis. The studies included in this review encompassed 5187 patients with HS and no controls. All studies used the Work Productivity and Activity Impairment questionnaire, reporting percentage scores for absenteeism, presenteeism, total work productivity impairment (TWPI) and total activity impairment (TAI). The pooled mean scores for HS were calculated as 10.17% [95% confidence interval (CI) 8.68\u201311.66] for absenteeism, 31.13% (95% CI 25.02\u201337.23) for presenteeism, 34.25% (95% CI 29.37\u201339.14) for TWPI and 42.23% (95% CI 38.56\u201345.89) for TAI. Significant heterogeneity was identified; most studies were of \u2018poor\u2019 to \u2018fair\u2019 quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current evidence suggests considerable impairment of workplace functioning in patients with HS. Our findings point to a significant unmet treatment need with respect to improving working capability in HS. The existing literature is inadequate to reliably assess the mechanisms underlying this effect or to comparatively assess the capabilities of HS therapies to improve workplace function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llae120","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T02:23:04Z","timestamp":1712370184000},"page":"1156-1163","source":"Crossref","is-referenced-by-count":13,"title":["The impact of hidradenitis suppurativa on work productivity and performance: a systematic review and\u00a0meta-analysis"],"prefix":"10.1093","volume":"49","author":[{"given":"Serena A","family":"Merchant","sequence":"first","affiliation":[{"name":"Tunbridge Wells Hospital, Maidstone and Tunbridge Wells NHS Foundation Trust , Tunbridge Wells , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0624-1246","authenticated-orcid":false,"given":"Syed F H","family":"Shah","sequence":"additional","affiliation":[{"name":"John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust , Oxford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"2024091818144771200_llae120-B1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091818144771200_llae120-B2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/12034754221088584","article-title":"Real-world moderate-to-severe hidradenitis suppurativa: decrease in disease burden with adalimumab","volume":"26","author":"Gulliver","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"2024091818144771200_llae120-B3","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/aje\/kwu078","article-title":"Hidradenitis suppurativa: number of diagnosed patients, demographic characteristics, and treatment patterns in the United States","volume":"179","author":"McMillan","year":"2014","journal-title":"Am J Epidemiol"},{"key":"2024091818144771200_llae120-B4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0007-1226(03)00177-2","article-title":"Hidradenitis suppurativa: pathogenesis and management","volume":"56","author":"Slade","year":"2003","journal-title":"Br J Plast Surg"},{"key":"2024091818144771200_llae120-B5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jaad.2009.09.021","article-title":"Hidradenitis suppurativa markedly decreases quality of life and professional activity","volume":"62","author":"Matusiak","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2024091818144771200_llae120-B6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjd.17101","article-title":"Impact of hidradenitis suppurativa on work loss, indirect costs and income","volume":"181","author":"Tzellos","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024091818144771200_llae120-B7","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jaad.2017.07.027","article-title":"Uncovering burden disparity: a comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa","volume":"77","author":"Hamzavi","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024091818144771200_llae120-B8","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/ijd.16163","article-title":"Hidradenitis suppurativa: racial and socioeconomic considerations in management","volume":"61","author":"Choi","year":"2022","journal-title":"Int J Dermatol"},{"key":"2024091818144771200_llae120-B9","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2024091818144771200_llae120-B10","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"2024091818144771200_llae120-B11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/bjd\/ljac027","article-title":"The impact of hidradenitis suppurativa on professional life","volume":"188","author":"Schneider-Burrus","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024091818144771200_llae120-B12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1159\/000517412","article-title":"Hidradenitis suppurativa in a large cohort of Italian patients: evaluation of the burden of disease","volume":"238","author":"Fabbrocini","year":"2022","journal-title":"Dermatology"},{"key":"2024091818144771200_llae120-B13","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/jdv.18163","article-title":"Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US","volume":"36","author":"Ingram","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091818144771200_llae120-B14","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/jdv.16132","article-title":"Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice","volume":"34","author":"Kimball","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091818144771200_llae120-B15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/jdv.15425","article-title":"HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa","volume":"33","author":"Peris","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091818144771200_llae120-B16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.18695","article-title":"The impact of hidradenitis suppurativa on work productivity and activity impairment","volume":"182","author":"Sandhu","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024091818144771200_llae120-B17","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jaad.2020.07.115","article-title":"Impact of hidradenitis suppurativa on work productivity and associated risk factors","volume":"84","author":"van Straalen","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024091818144771200_llae120-B18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ijd.14706","article-title":"Work productivity and activity impairment in patients with hidradenitis suppurativa: a cross-sectional study","volume":"59","author":"Yao","year":"2020","journal-title":"Int J Dermatol"},{"key":"2024091818144771200_llae120-B19","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2340\/00015555-3012","article-title":"Achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient-reported outcomes: post hoc analysis of pooled data from PIONEER I and II","volume":"98","author":"Kimball","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2024091818144771200_llae120-B20","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/jdv.15706","article-title":"Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: a prospective single centre study","volume":"33","author":"Prens","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091818144771200_llae120-B21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"2024091818144771200_llae120-B22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2340\/00015555-1082","article-title":"Psychosocial impact of hidradenitis \u00adsuppurativa: a qualitative study","volume":"91","author":"Esmann","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"2024091818144771200_llae120-B23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamadermatol.2019.0759","article-title":"Depression and anxiety in adults with hidradenitis suppurativa","volume":"155","author":"Machado","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2024091818144771200_llae120-B24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00000637-198509000-00005","article-title":"Surgical management of massice perianal hidradenitis suppurativa","volume":"15","author":"Ramastry","year":"1985","journal-title":"Ann Plast Surg"},{"key":"2024091818144771200_llae120-B25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14737167.2021.1895753","article-title":"Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study","volume":"22","author":"G\u00e1sp\u00e1r","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae120\/58244113\/llae120.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1156\/59183585\/llae120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1156\/59183585\/llae120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T14:14:57Z","timestamp":1726668897000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/10\/1156\/7642451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,4,9]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae120","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,4,9]]}}}